Adjuvant trastuzumab therapy for HER2-positive breast cancer

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

HER2 is overexpressed or gene amplified in 20%-25% of breast cancers. The anti-HER2 monoclonal antibody trastuzumab targets HER2-positive tumors, inhibiting proliferation and inducing cell death via extracellular and intracellular mechanisms. The clinical benefits observed with trastuzumab in the metastatic setting provided the rationale for assessing trastuzumab in the treatment of early breast cancer. Four large phase III adjuvant trials (NSABP B-31, NCCTG N9831, HERA, and BCIRG 006) investigated the efficacy and safety of 1 or 2 years of trastuzumab given in combination with or after standard adjuvant chemotherapy. The addition of 1 year of trastuzumab to adjuvant chemotherapy significantly improved disease-free survival (DFS) by 33%-52% and overall survival by 34%-41% in the 4 trials. The DFS benefits were observed regardless of age, nodal status, hormonal status, or tumor size in all trials. The cumulative incidence of congestive heart failure or cardiac death ranged from 0-0.9% in the control arms and 0-3.8% in the trastuzumab-containing arms. These were below the safety cutoff points set by the individual studies' independent data monitoring committees, indicating acceptable cardiac safety. Risk factors associated with cardiac dysfunction included baseline left ventricular ejection fraction level, hypertension, and older age. The addition of trastuzumab to adjuvant chemotherapy provides significant survival benefits with a positive benefit/risk ratio. Ongoing and planned trials correlated with basic science will enhance our understanding of HER2-positive disease, leading to treatment optimization and further improvements in patient outcomes.

Original languageEnglish
Pages (from-to)324-333
Number of pages10
JournalClinical Breast Cancer
Volume8
Issue number4
DOIs
StatePublished - Jan 1 2008
Externally publishedYes

Fingerprint

Breast Neoplasms
Adjuvant Chemotherapy
Safety
Therapeutics
Disease-Free Survival
Clinical Trials Data Monitoring Committees
Survival
Trastuzumab
Stroke Volume
Neoplasms
Cell Death
Heart Failure
Odds Ratio
Monoclonal Antibodies
Hypertension
Incidence
Genes

Keywords

  • c-Myc
  • Cardiac toxicity
  • Chromosome 17
  • Paclitaxel
  • Topoisomerase IIα

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Adjuvant trastuzumab therapy for HER2-positive breast cancer. / Jahanzeb, Mohammad.

In: Clinical Breast Cancer, Vol. 8, No. 4, 01.01.2008, p. 324-333.

Research output: Contribution to journalArticle

@article{16b467f8e3464310a2de85f4c365a69e,
title = "Adjuvant trastuzumab therapy for HER2-positive breast cancer",
abstract = "HER2 is overexpressed or gene amplified in 20{\%}-25{\%} of breast cancers. The anti-HER2 monoclonal antibody trastuzumab targets HER2-positive tumors, inhibiting proliferation and inducing cell death via extracellular and intracellular mechanisms. The clinical benefits observed with trastuzumab in the metastatic setting provided the rationale for assessing trastuzumab in the treatment of early breast cancer. Four large phase III adjuvant trials (NSABP B-31, NCCTG N9831, HERA, and BCIRG 006) investigated the efficacy and safety of 1 or 2 years of trastuzumab given in combination with or after standard adjuvant chemotherapy. The addition of 1 year of trastuzumab to adjuvant chemotherapy significantly improved disease-free survival (DFS) by 33{\%}-52{\%} and overall survival by 34{\%}-41{\%} in the 4 trials. The DFS benefits were observed regardless of age, nodal status, hormonal status, or tumor size in all trials. The cumulative incidence of congestive heart failure or cardiac death ranged from 0-0.9{\%} in the control arms and 0-3.8{\%} in the trastuzumab-containing arms. These were below the safety cutoff points set by the individual studies' independent data monitoring committees, indicating acceptable cardiac safety. Risk factors associated with cardiac dysfunction included baseline left ventricular ejection fraction level, hypertension, and older age. The addition of trastuzumab to adjuvant chemotherapy provides significant survival benefits with a positive benefit/risk ratio. Ongoing and planned trials correlated with basic science will enhance our understanding of HER2-positive disease, leading to treatment optimization and further improvements in patient outcomes.",
keywords = "c-Myc, Cardiac toxicity, Chromosome 17, Paclitaxel, Topoisomerase IIα",
author = "Mohammad Jahanzeb",
year = "2008",
month = "1",
day = "1",
doi = "10.3816/CBC.2008.n.037",
language = "English",
volume = "8",
pages = "324--333",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Adjuvant trastuzumab therapy for HER2-positive breast cancer

AU - Jahanzeb, Mohammad

PY - 2008/1/1

Y1 - 2008/1/1

N2 - HER2 is overexpressed or gene amplified in 20%-25% of breast cancers. The anti-HER2 monoclonal antibody trastuzumab targets HER2-positive tumors, inhibiting proliferation and inducing cell death via extracellular and intracellular mechanisms. The clinical benefits observed with trastuzumab in the metastatic setting provided the rationale for assessing trastuzumab in the treatment of early breast cancer. Four large phase III adjuvant trials (NSABP B-31, NCCTG N9831, HERA, and BCIRG 006) investigated the efficacy and safety of 1 or 2 years of trastuzumab given in combination with or after standard adjuvant chemotherapy. The addition of 1 year of trastuzumab to adjuvant chemotherapy significantly improved disease-free survival (DFS) by 33%-52% and overall survival by 34%-41% in the 4 trials. The DFS benefits were observed regardless of age, nodal status, hormonal status, or tumor size in all trials. The cumulative incidence of congestive heart failure or cardiac death ranged from 0-0.9% in the control arms and 0-3.8% in the trastuzumab-containing arms. These were below the safety cutoff points set by the individual studies' independent data monitoring committees, indicating acceptable cardiac safety. Risk factors associated with cardiac dysfunction included baseline left ventricular ejection fraction level, hypertension, and older age. The addition of trastuzumab to adjuvant chemotherapy provides significant survival benefits with a positive benefit/risk ratio. Ongoing and planned trials correlated with basic science will enhance our understanding of HER2-positive disease, leading to treatment optimization and further improvements in patient outcomes.

AB - HER2 is overexpressed or gene amplified in 20%-25% of breast cancers. The anti-HER2 monoclonal antibody trastuzumab targets HER2-positive tumors, inhibiting proliferation and inducing cell death via extracellular and intracellular mechanisms. The clinical benefits observed with trastuzumab in the metastatic setting provided the rationale for assessing trastuzumab in the treatment of early breast cancer. Four large phase III adjuvant trials (NSABP B-31, NCCTG N9831, HERA, and BCIRG 006) investigated the efficacy and safety of 1 or 2 years of trastuzumab given in combination with or after standard adjuvant chemotherapy. The addition of 1 year of trastuzumab to adjuvant chemotherapy significantly improved disease-free survival (DFS) by 33%-52% and overall survival by 34%-41% in the 4 trials. The DFS benefits were observed regardless of age, nodal status, hormonal status, or tumor size in all trials. The cumulative incidence of congestive heart failure or cardiac death ranged from 0-0.9% in the control arms and 0-3.8% in the trastuzumab-containing arms. These were below the safety cutoff points set by the individual studies' independent data monitoring committees, indicating acceptable cardiac safety. Risk factors associated with cardiac dysfunction included baseline left ventricular ejection fraction level, hypertension, and older age. The addition of trastuzumab to adjuvant chemotherapy provides significant survival benefits with a positive benefit/risk ratio. Ongoing and planned trials correlated with basic science will enhance our understanding of HER2-positive disease, leading to treatment optimization and further improvements in patient outcomes.

KW - c-Myc

KW - Cardiac toxicity

KW - Chromosome 17

KW - Paclitaxel

KW - Topoisomerase IIα

UR - http://www.scopus.com/inward/record.url?scp=53449093684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53449093684&partnerID=8YFLogxK

U2 - 10.3816/CBC.2008.n.037

DO - 10.3816/CBC.2008.n.037

M3 - Article

C2 - 18757259

AN - SCOPUS:53449093684

VL - 8

SP - 324

EP - 333

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 4

ER -